Metabolic Syndrome X Clinical Trial
Official title:
Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult
population suffers the disease.
Resveratrol is a substance found in many plants, including grapes, nuts and wine, but it's
also found in Polygonum cuspidatum. There is evidence that resveratrol consumption has
beneficial effects on glucose and lipids metabolism, blood pressure and body weight.
The aim of this study was to evaluate the effect of resveratrol on metabolic syndrome,
insulin sensitivity and insulin secretion.
The investigators hypothesis was that the administration of resveratrol modifies the
metabolic syndrome, insulin sensitivity and insulin secretion.
A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients
with a diagnosis of metabolic syndrome in accordance with the International Diabetes
Federation (IDF). Waist circumference, glucose, insulin levels, lipid profile, creatinine and
acid uric were evaluated after a 75 g of dextrose load.
12 received resveratrol, 500 mg, three times per day (1500 mg) before meals during 3 months.
The remaining 12 patients received placebo with the same prescription.
Area Under the Curve of glucose and insulin was calculated as well as total insulin secretion
(insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin
sensitivity (Matsuda index).
This protocol was approved by a local ethics committee and written informed consent was
obtained from all volunteers.
Results are presented as mean and standard deviation. Intra and inter group differences were
tested using the Wilcoxon signed-rank and Mann-Whitney U-test respectively; p≤0.05 was
considered significant.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02702375 -
Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases
|
N/A | |
Completed |
NCT02649348 -
Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome
|
N/A | |
Completed |
NCT02918422 -
Controlled Clinical Study to Determine Novel Health Benefits of Cheese Consumption
|
N/A | |
Completed |
NCT02356952 -
Effect of a Low Glycemic Index on Metabolic Syndrome
|
N/A | |
Completed |
NCT02459691 -
Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos)
|
N/A | |
Completed |
NCT02337933 -
Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome
|
Phase 2 | |
Completed |
NCT02402985 -
Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics
|
N/A | |
Completed |
NCT01694056 -
Soy Protein Intake and the Metabolic Syndrome
|
N/A | |
Completed |
NCT00344903 -
Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort
|
N/A | |
Recruiting |
NCT00408824 -
Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study)
|
N/A | |
Completed |
NCT00362908 -
Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome
|
N/A | |
Completed |
NCT00395486 -
ROMEO (Rosuvastatin in Metabolic syndrOme)
|
Phase 4 | |
Completed |
NCT00140816 -
Dairy Products and Metabolic Effects (Norwegian Part)
|
N/A | |
Completed |
NCT00455325 -
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
|
Phase 2 | |
Completed |
NCT00166036 -
Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells
|
Phase 2 | |
Completed |
NCT00101517 -
Partnership Programs to Reduce Ethnic Differences in the Risk of Cardiovascular Disease
|
N/A | |
Recruiting |
NCT00177892 -
Obstructive Sleep Apnea (OSA) and Metabolic Syndrome: Role of Oxidative Stress
|
N/A | |
Completed |
NCT00074451 -
Genomewide Search for Loci Underlying Metabolic Syndrome
|
||
Completed |
NCT00073775 -
Epidemiology of Stress and the Metabolic Syndrome
|
N/A | |
Completed |
NCT00200993 -
Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE I)
|
Phase 2 |